Meggan Jones, in Bonne Terre, MO - Occupational Therapist

Meggan Jones, is a Occupational Therapist based in Bonne Terre, Missouri. Meggan Jones is licensed to practice in Missouri (license number 2008021472) and her current practice location is 300 Berry Rd, Bonne Terre, Missouri. She can be reached at her office (for appointments etc.) via phone at (573) 358-2247.

NPI number for Meggan Jones is 1972750255 and her current mailing address is 300 Berry Rd, Bonne Terre, Missouri. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1972750255.

Contact Information

	Meggan Jones,
	300 Berry Rd, Bonne Terre, MO 63628-3580
	(573) 358-2247
	Not Available

Healthcare Provider's Profile

Full Name	Meggan Jones
Gender	Female
Speciality	Occupational Therapist
Location	300 Berry Rd, Bonne Terre, Missouri
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1972750255
Provider Enumeration Date: 08/19/2008
Last Update Date: 08/19/2008

Medical Identifiers

Medical identifiers for Meggan Jones such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1972750255	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
225X00000X	Occupational Therapist	2008021472 (Missouri)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Meggan Jones is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Meggan Jones, 300 Berry Rd, Bonne Terre, MO 63628-3580 Ph: (573) 358-2247	Meggan Jones, 300 Berry Rd, Bonne Terre, MO 63628-3580 Ph: (573) 358-2247

News Archive

Latuda tablets receive FDA approval for treatment of adults with schizophrenia

The U.S. Food and Drug Administration today approved Latuda (lurasidone HCl) tablets for the treatment of adults with schizophrenia.

Johnson & Johnson's sales increase 3.5% to $18.1 billion in first quarter 2014

Johnson & Johnson today announced sales of $18.1 billion for the first quarter of 2014, an increase of 3.5% as compared to the first quarter of 2013. Operational results increased 5.3% and the negative impact of currency was 1.8%. Domestic sales increased 2.2%. International sales increased 4.5%, reflecting operational growth of 7.9% and a negative currency impact of 3.4%.

Recent releases in Global Health

African Nations Rightly Proceed With DDT Plans: "Environmental activists inside and outside UNEP love to hate DDT and will seemingly stop at nothing to ensure it is never produced or used. But there is a macabre irony in their anti-DDT campaigns. With all the technological advancement of the 21st century that now ensures the average person born today will live longer than at any time in human history, SADC will be producing a chemical first synthesized in the 1800s.

Short chain fatty acid supplementation improves stroke recovery, mice study shows

Supplementing the body's short chain fatty acids can improve stroke recovery, according to research in mice recently published in JNeurosci. Short chain fatty acid supplementation may be a non-invasive addition to stroke rehabilitation therapies.

Survival for patients with HCC increases with radioembolization

Analysis revealed survival for patients with hepatocellular carcinoma (HCC) is achievable using 90Y-resin microsphere radioembolization. The analysis conducted at multiple centers across Europe showed that the procedure is likely to provide survival benefit across different tumor stages, including patients with advanced liver cancer and with limited treatment options.

Meggan Jones, - Occupational Therapist in Bonne Terre, MO